vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and ServisFirst Bancshares, Inc. (SFBS). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $159.0M, roughly 1.2× ServisFirst Bancshares, Inc.). ServisFirst Bancshares, Inc. runs the higher net margin — 52.2% vs -14.6%, a 66.8% gap on every dollar of revenue. Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 17.7%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
ServisFirst Bancshares, Inc. is a U.S.-based bank holding company operating full-service banking locations primarily across the Southeastern United States. It offers a full suite of commercial banking, consumer banking, wealth management, and mortgage lending services to small and medium-sized businesses, professional clients, and individual consumers.
AXSM vs SFBS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $159.0M |
| Net Profit | $-28.6M | $83.0M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | — |
| Net Margin | -14.6% | 52.2% |
| Revenue YoY | 65.0% | — |
| Net Profit YoY | 61.9% | 31.2% |
| EPS (diluted) | $-0.55 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $159.0M | ||
| Q4 25 | $196.0M | $162.2M | ||
| Q3 25 | $171.0M | $136.3M | ||
| Q2 25 | $150.0M | $132.1M | ||
| Q1 25 | $121.5M | $131.8M | ||
| Q4 24 | $118.8M | $131.9M | ||
| Q3 24 | $104.8M | $123.7M | ||
| Q2 24 | $87.2M | $114.8M |
| Q1 26 | — | $83.0M | ||
| Q4 25 | $-28.6M | $86.4M | ||
| Q3 25 | $-47.2M | $65.6M | ||
| Q2 25 | $-48.0M | $61.4M | ||
| Q1 25 | $-59.4M | $63.2M | ||
| Q4 24 | $-74.9M | $65.2M | ||
| Q3 24 | $-64.6M | $59.9M | ||
| Q2 24 | $-79.3M | $52.1M |
| Q1 26 | — | — | ||
| Q4 25 | -13.8% | 66.3% | ||
| Q3 25 | -27.0% | 57.8% | ||
| Q2 25 | -24.5% | 58.0% | ||
| Q1 25 | -46.9% | 60.0% | ||
| Q4 24 | -61.1% | 60.2% | ||
| Q3 24 | -59.8% | 58.5% | ||
| Q2 24 | -89.5% | 58.0% |
| Q1 26 | — | 52.2% | ||
| Q4 25 | -14.6% | 59.0% | ||
| Q3 25 | -27.6% | 48.1% | ||
| Q2 25 | -32.0% | 46.5% | ||
| Q1 25 | -48.9% | 48.0% | ||
| Q4 24 | -63.1% | 52.9% | ||
| Q3 24 | -61.7% | 48.4% | ||
| Q2 24 | -91.0% | 45.4% |
| Q1 26 | — | $1.52 | ||
| Q4 25 | $-0.55 | $1.58 | ||
| Q3 25 | $-0.94 | $1.20 | ||
| Q2 25 | $-0.97 | $1.12 | ||
| Q1 25 | $-1.22 | $1.16 | ||
| Q4 24 | $-1.54 | $1.19 | ||
| Q3 24 | $-1.34 | $1.10 | ||
| Q2 24 | $-1.67 | $0.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $1.8B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $1.9B |
| Total Assets | $689.8M | $18.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.8B | ||
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $88.3M | $1.8B | ||
| Q3 25 | $73.7M | $1.8B | ||
| Q2 25 | $73.1M | $1.7B | ||
| Q1 25 | $53.2M | $1.7B | ||
| Q4 24 | $57.0M | $1.6B | ||
| Q3 24 | $92.9M | $1.6B | ||
| Q2 24 | $102.9M | $1.5B |
| Q1 26 | — | $18.2B | ||
| Q4 25 | $689.8M | $17.7B | ||
| Q3 25 | $669.3M | $17.6B | ||
| Q2 25 | $639.8M | $17.4B | ||
| Q1 25 | $596.7M | $18.6B | ||
| Q4 24 | $568.5M | $17.4B | ||
| Q3 24 | $561.5M | $16.4B | ||
| Q2 24 | $548.2M | $16.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | — |
| Free Cash FlowOCF − Capex | $-18.7M | — |
| FCF MarginFCF / Revenue | -9.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $355.2M | ||
| Q3 25 | $1.0M | $140.9M | ||
| Q2 25 | $-32.4M | $67.6M | ||
| Q1 25 | $-43.4M | $48.0M | ||
| Q4 24 | $-26.2M | $252.9M | ||
| Q3 24 | $-18.6M | $84.0M | ||
| Q2 24 | $-30.1M | $48.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.11× | ||
| Q3 25 | — | 2.15× | ||
| Q2 25 | — | 1.10× | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 3.88× | ||
| Q3 24 | — | 1.40× | ||
| Q2 24 | — | 0.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
SFBS
| Net Interest Income | $148.1M | 93% |
| Noninterest Income | $10.8M | 7% |
